Advertisement


Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in patients with advanced solid tumors (Abstract 20).



Related Videos

Prostate Cancer
Immunotherapy

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inh...

Issues in Oncology
Immunotherapy

Mary L. Disis, MD, on Basics of Immunology: An Overview

Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...

Bladder Cancer
Immunotherapy

Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.

Hematologic Malignancies
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.

Solid Tumors
Immunotherapy

Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...

Advertisement

Advertisement



;
Advertisement